Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals.
Dosimetry
FDG-PET/CT
Lu-177 PSMA
PSMA-PET/CT
PSMA-based radioligand therapy
Prostate cancer
mCRPC
Journal
PET clinics
ISSN: 1879-9809
Titre abrégé: PET Clin
Pays: United States
ID NLM: 101260152
Informations de publication
Date de publication:
27 Apr 2024
27 Apr 2024
Historique:
medline:
29
4
2024
pubmed:
29
4
2024
entrez:
28
4
2024
Statut:
aheadofprint
Résumé
Prostate cancer is the most common malignancy in men worldwide, with an estimated 174,650 new cases per year in the United States, and the second cancer-related cause of death, after lung cancer, with 31,620 deaths per year. While the 5 year survival rate for prostate cancer in patients without metastatic spread is nearly 100%, those with distant metastases have 5 year survival rates of approximately 30%. Initial diagnosis and assessment are based on PSA levels, Gleason score (derived from prostate biopsy), and advanced imaging modalities, including prostate MR imaging and PSMA-PET/computed tomography in patients with high-risk features.
Identifiants
pubmed: 38679550
pii: S1556-8598(24)00026-9
doi: 10.1016/j.cpet.2024.03.011
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors declare no conflict of interest